Savvy Updates, 11/4/24: O5/iPhone, Abbott CGM & MRIs, FDA Rejects Sotagliflozin, Chinese Stem-Cell Therapies, Semaglutide & Arthritis, Beta Bionics & Libre 3 Plus, AI & Diabetic Cardiomyopathy, Insulcloud & Insulin Pens, Dexcom CCO Retires

Savvy Updates, 11/4/24: O5/iPhone, Abbott CGM & MRIs, FDA Rejects Sotagliflozin, Chinese Stem-Cell Therapies, Semaglutide & Arthritis, Beta Bionics & Libre 3 Plus, AI & Diabetic Cardiomyopathy, Insulcloud & Insulin Pens, Dexcom CCO Retires

Nov 4, 2024 | Advocacy, Diabetes Business, Featured, Research News, Technology Updates

In this week’s issue of The Savvy Diabetic:  Omnipod 5 & the iPhone App Abbott CGM Sensors OK in MRI FDA Rejects Sotagliflozin for T1D Chinese Stem Cell-Based Therapies Semaglutide for Knee Osteoarthritis Pain Beta Bionics Launches iLet with Abbott...
Skip to content